Skip to main content

Table 1 Demographics and baseline characteristics of patients recruited for this study

From: Safety of intravenous administration of hydrogen-enriched fluid in patients with acute cerebral ischemia: initial clinical studies

 

Total

Group I

Group II

 

n = 38

n = 27

n = 11

Male gender, n (%)

27 (71)

19 (70)

8 (73)

Age, years

69.4 ± 10.7

70.9 ± 11.2

65.5 ± 7.9

Past history, n (%)

   
 

Hypertension

25 (66)

19 (70)

6 (55)

 

Diabetes mellitus

16 (42)

9 (33)

7 (64)

 

Hyperlipidemia

7 (18)

4 (15)

3 (27)

 

Smoking

8 (21)

4 (15)

3 (27)

 

Atrial fibrillation

11 (29)

11 (41)

0 (0)

 

Ischemic stroke

11 (29)

9 (33)

2 (18)

 

Intracerebral hemorrhage

2 (5)

1 (4)

1 (9)

 

Subarachnoid hemorrhage

0 (0)

0 (0)

0 (0)

Infarct side, n (%)

   
 

Right

20 (53)

13 (48)

7 (64)

 

Left

18 (47)

14 (52)

4 (36)

Baseline NIHSS score, mean

8.2 ± 7.5

10 ± 8.2

3.9 ± 2.4

Interval from onset to treatment with edaravone and hydrogen, h

16 ± 18.1

14.9 ± 18.7

18.8 ± 6.3

Duration of treatment with edaravone and hydrogen, d

10.8 ± 3.4

10.7 ± 3.5

11.1 ± 3

Laboratory data

   
 

HbA1C,%

6.3 ± 1.7

6 ± 1.4

7 ± 2

 

BG, mg/dl

145.2 ± 58.2

134 ± 48.9

171.6 ± 68.8

 

TG, mg/dl

116.7 ± 61.3

121 ± 67.7

107.8 ± 43.7

 

TC, mg/dl

194.3 ± 43.4

186.6 ± 38.3

217.3 ± 49.4

 

LDL, mg/dl

114.3 ± 33.7

109 ± 25.7

126.5 ± 44.7

 

UA, mg/dl

5.3 ± 1.4

5.2 ± 1.4

5.6 ± 0.9

 

PT-INR

1.14 ± 0.3

1.2 ± 0.3

1.1 ± 0.06

 

APTT, seconds

30.7 ± 3.9

31 ± 4.1

30.1 ± 3.2

 

Fibrinogen, mg/dl

336.7 ± 101.9

333.6 ± 107.4

349 ± 74.9

 

Hct (%)

41.3 ± 6.4

40.7 ± 6.7

42.8 ± 5.3

  1. BG, blood glucose; TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein; UA, uric acid; PT-INR, prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time; Hct, hematocrit.